Novo Nordisk files annual report with the SEC
31 janv. 2024 07h34 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 31 January 2024 – Novo Nordisk A/S has filed its Annual Report 2023 on Form 20-F for the financial year 2023 with the US Securities and Exchange Commission (SEC), incorporating by...
Novo Nordisk's sales increased by 31% in Danish kroner and by 36% at constant exchange rates to DKK 232.3 billion in 2023
31 janv. 2024 01h30 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 31 January 2024 - Financial report for the period 1 January 2023 to 31 December 2023 ...
Novo Nordisk A/S - share repurchase programme
30 janv. 2024 10h28 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 30 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
22 janv. 2024 07h01 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 22 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
15 janv. 2024 05h43 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 15 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
09 janv. 2024 11h15 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 9 January 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes
08 janv. 2024 07h49 HE
|
Novo Nordisk A/S
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in...
Novo Nordisk A/S - share repurchase programme
08 janv. 2024 06h11 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 08 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases
04 janv. 2024 05h59 HE
|
Novo Nordisk A/S
Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity managementCellarity collaboration will build upon initial work and...
Novo Nordisk A/S - share repurchase programme
22 déc. 2023 06h52 HE
|
Novo Nordisk A/S
Bagsværd, Denmark, 22 December 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...